Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.
1 report, 1 independent
Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.Sub-event
Cytokinetics' drug is under FDA review following data presentation in Madrid, Spain.1 source
Keep exploring
The entities involved
-
Cytokinetics
company in South San Francisco, United States
- FDA
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaESC 2025: Cytokinetics’ oHCM drug outperforms SoC beta blockers Cytokinetics’ aficamten outperformed standard of care (SoC) in a Phase III trial in patients with symptomatic obstructive hypertrophic